Azitra (AZTR) Stock Price, News & Analysis

Company Overview

Azitra, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapies for dermatological conditions. The company’s platform leverages proprietary bacterial strains to modulate the skin microbiome, with the goal of restoring healthy skin function and alleviating symptoms of inflammatory and infectious skin disorders.

Azitra’s lead product candidates include AZT-02, a topical formulation designed to treat atopic dermatitis by delivering beneficial commensal bacteria directly to affected skin. Additional programs in the pipeline are targeting acne, seborrheic dermatitis, and other skin ailments where dysbiosis of the microbiome plays a key role. These candidates are being evaluated in preclinical studies and early-stage clinical trials.

Founded in 2017 through a spin-out of microbiome research from Harvard University, Azitra is headquartered in Cambridge, Massachusetts. The company also maintains research collaborations across Europe and North America, positioning itself to conduct multi-site clinical development and ultimately support regulatory filings in both the United States and the European Union.

Azitra’s leadership team is led by President and CEO David Whitehouse, who brings extensive experience in biotech operations and clinical development. The scientific advisory board comprises experts in dermatology, microbiology, and translational medicine, guiding the company’s R&D strategy and ensuring rigorous development of its microbiome therapeutics.

Key Stats

• Today's Range: $0.22 to $0.24
• 50-Day Range: $0.23 to $0.31
• 52-Week Range: $0.22 to $12.00
• Volume: 837,488 shs
• Average Volume: 3.22 million shs
• Market Capitalization: $3.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Azitra Stock Analysis - MarketRank™

Azitra scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Azitra.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Azitra are expected to grow in the coming year, from ($2.78) to ($0.95) per share.

Price to Book Value per Share Ratio

Azitra has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.47% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently increased by 172.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Azitra does not currently pay a dividend.

Dividend Growth

Azitra does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.47% of the float of Azitra has been sold short.

Short Interest Ratio / Days to Cover

Azitra has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Azitra has recently increased by 172.66%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for AZTR on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Azitra insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.25% of the stock of Azitra is held by insiders.

Percentage Held by Institutions

Only 11.16% of the stock of Azitra is held by institutions.

AZTR Stock Analysis - Frequently Asked Questions

How have AZTR shares performed this year?

Azitra's stock was trading at $0.4448 on January 1st, 2025. Since then, AZTR shares have decreased by 48.5% and is now trading at $0.2290.

How were Azitra's earnings last quarter?

Azitra, Inc. (NYSEAMERICAN:AZTR) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.17) earnings per share for the quarter, beating analysts' consensus estimates of ($0.48) by $0.31.

When did Azitra's stock split?

Azitra's stock reverse split on Monday, July 1st 2024.The 1-30 reverse split was announced on Monday, July 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Azitra?

Shares of AZTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Azitra own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Azitra investors own include NVIDIA (NVDA), Broadcom (AVGO), Tesla (TSLA), Advanced Micro Devices (AMD), CrowdStrike (CRWD), FedEx (FDX) and Intel (INTC).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 7/14/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:AZTR
• CIK: 1701478
• Web: azitrainc.com
• Phone: 203-646-6446
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.97 million
• Net Margins: N/A
• Pretax Margin: -113,662.50%
• Return on Equity: -183.05%
• Return on Assets: -135.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.03
• Quick Ratio: 3.03

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 394.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.75 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 17,230,000
• Free Float: 17,183,000
• Market Cap: $3.95 million
• Optionable: Not Optionable
• Beta: -1.59